MAPK8 and B-cell non-Hodgkin lymphoma: Elevated JNK activity is an established contributor to malignancy progression and chemo/radiotherapy resistance in many cancers in which JNK is transiently activated, such as B-cell lymphoma, osteosarcoma, breast, lung, skin, and pancreatic cancer [13,27,44,45,46].